CRVS vs RGNX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRVS Captures Institutional Edge (3โ1 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Corvus Pharmaceuticals, Inc. (CRVS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while RGNX counters with relative strength in Valuation. Fundamentally, CRVS trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus RGNX at N/M Forward P/E and -120.4% operating margin (-69.2% YoY). In options structure, CRVS sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRVS | RGNX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $895.8M | $500.9M | Larger Scale | CRVS |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -69.2% | Higher Growth | CRVS |
| Operating Margin (TTM) Profitability | 0.0% | -120.4% | Higher Margin | CRVS |
| Net Profit Margin Profitability | 0.0% | -113.9% | Higher Margin | CRVS |
| Return on Equity (ROE) Capital Efficiency | -45.9% | -113.2% | Higher ROE | CRVS |
| 52-Week Range Position Momentum | 21% ($6โ$27) | 19% ($5โ$16) | Stronger Trend | CRVS |
| Beta / 30D Volatility Risk Regime | 1.87ฮฒ ยท 71% Vol | 1.82ฮฒ ยท 76% Vol | Lower Realized Risk | CRVS |
| Unified Institutional Score Composite Signal | 34.3 / 100 (SELL) | 45.3 / 100 (HOLD) | Higher Composite | RGNX |